Aggressive B-cell lymphomas: female BMI tied to R-CHOP-14 outcomes

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • In women aged >60 years with aggressive B-cell lymphomas treated with R-CHOP-14 (rituximab + cyclophosphamide, doxorubicin, vincristine, and prednisolone at 14-day intervals), obesity was a risk factor for inferior event-free survival (EFS), PFS, and OS.

Why this matters

  • Data regarding outcomes in obese patients with lymphoma are inconsistent.

Study design

  • RICOVER-60 data for 576 patients with aggressive B-cell lymphomas who received R-CHOP-14.
  • Results were analyzed according to BMI (≥30 kg/mvs <30 kg/m2) and sex.
  • All patients were aged >60 years.
  • Funding: Deutsche Krebshilfe.

Key results

  • 42% of patients were overweight (BMI: ≤25 to <30 kg/m2), 19% of patients were obese (BMI: ≥30 kg/m2) at treatment initiation.
  • No significant difference in all patients vs male patients for EFS, PFS, and OS.
  • Superior outcomes in nonobese females vs obese females for EFS (P=.041), PFS (P=.038), and OS (P=.031); results were confirmed in multivariate analyses adjusted for International Prognostic Index risk factors.
  • Some centers capped chemoimmunotherapy dose in patients with body surface area (BSA) >2 m2; no significant difference in EFS, PFS, or OS, regardless of sex or cyclophosphamide reduction due to high BSA.

Limitations

  • Retrospective data.